B of A Securities Maintains Buy on PTC Therapeutics, Lowers Price Target to $93
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Tazeen Ahmad maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and lowers the price target from $97 to $93.
B of A Securities analyst Tazeen Ahmad maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and lowers the price target from $97 to $93.